Our Approach

Malignant tumors need blood vessels to get nutrients and oxygen, and they use lymphatic vessels to metastasize. Blocking validated targets in angiogenesis and lymphangiogenesis with highly specific and safe antibodies, deprives tumors of their ability to grow and metastasize.

KB Platform

Sophisticated target selection and mAb development designed to address multiple pathological mechanisms in parallel

KB Pipeline

Portfolio of 3 patent protected mAb with promising in vivo Efficacy



  • Pagnuzzi-Boncompagni, M, Picco, V, Vial, V, Planas-Bielsa, V, Vandenberghe, A, Daubon, T, Derieppe, MA, Montemagno, C, Durivault, J, Grépin, R, Martial, S, Doyen, J, Gavard, J and Pagès, G. Cancers 2022 ;14(1):70.


1-        Hagege A, Ambrosetti D, Boyer J, Bozec A, Doyen J, Chamorey E, He X, Bourget I, Rousset J, Saada E, Rastoin O, Parola J, Luciano F, Cao Y, Pagès G*, Dufies M* (*codirection of the work). The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy. Theranostics. 2021 Sep 21;11(19):9571-9586.

2-        Dumond A, Montemagno C, Vial V, Grépin R, Pagès GAnti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas. Cells. 2021 May 17;10(5):1222.

3-      Dumond, A, Brachet, E, Durivault, J, Vial, V, Puszko, AK, Lepelletier, Y, Montemagno, C, Pagnuzzi-Boncompagni, M, Hermine, O, Garbay, C, Lagarde, N, Montes, M, Demange, L, Grépin, R and Pagès, G. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma Journal of Experimental & Clinical Cancer Research 2021 40:33

4-      Dufies M, Verbiest A, Cooley L, Ndiaye P, Viotti J, He X, Nottet N, Souleyreau W, Hagege A, Torrino S, Parola J, Giuliano S, Borchiellini D, Schiappa R, Mograbi B, Zucman-Rossi J, Bensalah K, Ravaud A, Auberger P, Bikfalvi A, Chamorey E, Rioux-Leclercq N, Mazure N, Beuselinck B, Co Y, Bernhard JC, Ambrosetti D and Pagès G. A novel mechanism of HIF2-dependent Plk1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma. Commun Biol. 2021 Feb 5;4(1):166.

5-      Ambrosetti D, Coutts M, Paoli C, Durand M, Borchiellini D, Montemagno C, Rastoin O, Borderie A, Grepin R, Rioux-Leclercq N, Bernhard JC, Pagès G*, Dufies M*. Cancer associated fibroblasts in Renal Cell Carcinoma: implication in prognosis and resistance to antiangiogenic therapy.  BJU Int. 2021 Jun 9. doi: 10.1111/bju.15506.

6-        Cooley LS, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K, Falciani F, Dufies M, Lambrechts D, Modave E, Chalopin-Fillot D, Pineau R, Ambrosetti D, Bernhard JC, Ravaud A, Négrier S, Ferrero JM, Pagès G, Benzekry S, Nikolski M, Bikfalvi A. Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression Mol Cancer. 2021 Oct 20;20(1):136.


1-       Montemagno C, Hagege A, Borchiellini D, Thamphya B, Rastoin O, Ambrosetti D, Iovanna J, Rioux-Leclercq N, Porta C, Negrier S, Ferrero JM, Chamorey E, Pagès G* and Dufies M* (* co-direction of the work). Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma Oncoimmunology. 2020 Nov 25;9(1):1846901.

2-       Penco-Campillo M, Comoglio Y, Feliz Morel ÁJ, Hanna R, Durivault J, Leloire M, Mejias B, Pagnuzzi M, Morot A, Burel-Vandenbos F, Selby M, Williamson D, Clifford SC, Claren A, Doyen J, Picco V, Martial S, Pagès GVEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells. Commun Biol. 2020 Oct 16;3(1):579.

3-       Grépin R, Guyot M, Dumond A, Durivault J, Ambrosetti D, Roussel JF, Dupré F, Quintens H, Pagès GThe combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma : the role of a synonymous mutation of the EGFR receptor. Theranostics. 2020 Jan 1;10(3):1107-1121.

4-       Montemagno C, Pagès G. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs.  Front Cell Dev Biol. 2020 Jul 7;8:584.

5-       Dumond A, Pagès GNeuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment.  Front Cell Dev Biol. 2020 Jul 17; 8:662.

6-       Rastoin O, Pagès G, Dufies, M, Experimental Models in Neovascular Age Related Macular Degeneration. Int J Mol Sci. 2020 Jun 29;21(13):4627.

7-       Dumond A, Demange L, Pagès G[Neuropilins: relevant therapeutic targets to improve the treatment of cancers]. Med Sci (Paris). 2020 May;36(5):487-496.

8-       Fabbri L, Dufies M, Lacas-Gervais S, Gardie B, Gad-Lapiteau S, Parola J, Nottet N, Meyenberg Cunha de Padua M, Contenti J, Borchiellini D, Ferrero JM, Leclercq NR, Ambrosetti D, Mograbi B, Richard S, Viotti J, Chamorey E, Sadaghianloo N, Rouleau M, Craigen WJ, Mari B, Clavel S, Pagès G, Pouysségur J, Bost F, Mazure NM. Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients. Theranostics. 2020 Feb 3;10(6):2696-2713.


1-         Ndiaye PD, Dufies M, Giuliano S, Douguet L, Grépin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pagès G. VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics 2019; 9(3):661-675.

2-         Ndiaye PD, Pagès GVEGF-C and lymphatic vessels: a double-edged sword in tumor development and metastasis. Med Sci (Paris). 2019 Feb;35(2):132-137.

3-         Brachet E, Dumond A, Liu WQ, Fabre M, Selkti M, Raynaud F, Hermine O, Benhida R, Belmont P, Garbay C, Lepelletier Y, Ronco C, Pagès G, Demange L. Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agent. Bioorg Med Chem Lett. 2019 Dec 15;29(24):126710.


1-        Pagès, G. The path to « the Golden Age » for the treatment of metastatic renal cell carcinoma. Oncotarget 2018 3;9(60):31564-31565.

2-        Dufies,M, Nollet, M, Ambrosetti, D, Viotti, J, Borchiellini, D, Parola, J, Helley-Russick, D, Ravaud, A, Bernhard, JC, Bardin, N, Dignat-george, F, Rioux-Leclercq, N, Oudard, S, Negrier, S, Ferrero, JM, Chamorey, E, Blot-Chabaud,M*and Pagès, G. Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. Theranostic, 2018, 28;8(9):2447-2458.

3-        Polena, H*, Creuzet J*, Dufies M*, Sidibé A, Khalil-Mgharbel1 A, Salomon A, Deroux A, Quesada JL, Roelants C, Filhol O, Cochet C, Blanc E, Ferlay-Segura E, Borchiellini D, Ferrero JM, Escudier B, Négrier S, Pagès, G*, Vilgrain, I*. (* Co-premiers, ¤ Co-derniers auteurs). Br J Cancer, 2018, 118(9):1179-1188.

4-         Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pages G, Burel-Vandenbos F, Mazure NM. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS One. 2018 Feb 26;13(2):e0193477


1-       Dufies, M*, Giuliano, S*, Viotti, J, Borchiellini, D, Cooley, L, Ambrosetti, D, Guyot, M, Diogop Ndiaye, P, Parola, J, Claren, A, Schiappa, R, Gal, J, Frangeul, A, Jacquel, A, Cassuto, O, Grépin, R, Auberger, P, Bikfalvi, A, Milano, G, Escudier, B, Rioux-Leclercq, N, Porta, C, Négrier, S, Chamorey, E, Ferrero, JM and Pagès, G. CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas, Br J Cancer 2017, 1;77(5):1212-1226.

2-       Lupu-Plesu, M*, Claren, A*, Martial, S, Diogop N’Diaye, P, Lebrigand, K, Pons, N, Ambrosetti, D, Peyrottes, I, Feuillade, J, Hérault, J, Dufies, M, Doyen. Jand Pagès, G. Effects of proton versus photon irradiation on (lymph)angiogenic, inflammatory, proliferative and anti-tumor immune responses in head and neck squamous cell carcinoma, Oncogenesis 2017 3;6(7):e354.

3-       Dufies M, Giuliano S, Ambrosetti D, Claren A, Diogop Ndiaye P, Mastri M, Moghrabi W, Cooley LS, Ettaiche M, Chamorey E, Parola J, Vial V, Lupu-Plesu M, Bernhard JC, Ravaud A, Borchiellini D, Ferrero JM, Bikfalvi A, Ebos JM, Khabar KS, Grepin R, Pagès GSunitinib stimulates expression of VEGFC by tumor cells and promotes lymphangiogenesis in clear cell renal cell carcinomas. Cancer Res. 2017 Mar 1;77(5):1212-1226

4-       Guyot M, Hilmi C, Ambrosetti D, Merlano M, Lo Nigro C, Durivault J, Grépin R, Pagès G Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies. Oncotarget. 2017 Feb 7;8(6):9174-9188

5-       Masoud V, Pagès G. Targeted therapies in breast cancer: New challenges to fight against resistance. World J Clin Oncol. 2017 Apr 10;8(2):120-134.

6-       Ambrosetti D, Dufies M, Dadone B, Durand M, Borchiellini D, Amiel J, Pouyssegur J, Rioux-Leclercq N, Pagès G, Burel-Vandenbos F, Mazure NM. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma. PLoS One. 2018 Feb 26;13(2):e0193477.


1-      Montemagno, C, Durivault, J, Pagès, G (2020). New splice variant isoform of VEGF. EP20204454.1

2-      Dumond, A, Grépin, R, Pagès, G (2020). New anti-VEGFC antibodies and uses thereof: EP20305296.4.

3-   Grépin, R, Pagès, G (2013): Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications. WO 2014/184384.